Drug discovery and development company SCYNEXIS, Inc., today announced
that it plans to commence a road show on March 24, 2014 for the proposed
initial public offering of shares of its common stock. SCYNEXIS has
filed a registration statement with the Securities and Exchange
Commission to offer 4,230,800 shares of its common stock to the public.
The initial public offering price is currently expected to be between
$12.00 and $14.00 per share. The underwriters have an option to purchase
an additional 634,620 shares of common stock at the initial public
offering price less the underwriting discount, within 30 days from the
date of the offering.
An application has been made to list the common stock of SCYNEXIS on the
NASDAQ Global Market under the symbol "SCYX."
RBC Capital Markets and Canaccord Genuity are serving as joint
bookrunning managers. In addition, JMP Securities is participating as
lead manager in the offering. The offering of SCYNEXIS common stock will
be made only by means of a prospectus. A registration statement relating
to these securities has been filed with the Securities and Exchange
Commission but has not yet become effective. hese securities may not be
sold nor may offers to buy be accepted prior to the time the
registration statement becomes effective.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
When available, a copy of the preliminary prospectus relating to the
proposed initial public offering may be obtained on the SEC EDGAR
Filings Website: http://www.sec.gov/edgar/searchedgar/companysearch.html.
Until then, you may obtain more information by contacting RBC Capital
Markets, Attention: Prospectus Department, Three World Financial Center,
200 Vesey Street 8th Floor, New York, NY 10281, telephone (877) 822-4089
or Canaccord Genuity Inc., Attn: Syndicate Department, 99 High Street,
12th Floor, Boston, MA 02110, telephone (617) 371-3900.
SCYNEXIS is a pharmaceutical company committed to the discovery,
development and commercialization of novel anti-infectives to address
significant unmet therapeutic needs. We are developing our lead product
candidate, SCY-078, as a novel oral and intravenous (IV) drug for the
treatment of serious and life-threatening invasive fungal infections in
humans. In addition, we have clinical and preclinical programs based on
the use of cyclophilin inhibitors to treat viral diseases, as well as
contract research and development services in primarily in the field of
animal health. www.scynexis.com
[ Back To NFVZone's Homepage ]